Oncogenic B-RAF V600E promotes anchorage-independent survival of human melanocytes

Journal of Investigative Dermatology

Volumn 130, Issue 8, 2010, Pages 2144-2147

  Becker, Therese M ^a   Philipsz, Suzanah ^a   Scurr, Lyndee L ^a   Fung, Carina ^a   Haferkamp, Sebastian ^b   Kefford, Richard F ^a,c   Rizos, Helen ^a  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c MELANOMA INSTITUTE AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE;

ANOIKIS; CELL ADHESION; CELL ANCHORAGE; CELL CYCLE ARREST; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FIBROBLAST; HUMAN; HUMAN CELL; LETTER; MELANOCYTE; ONCOGENE; ONCOGENE N RAS; PRIORITY JOURNAL; WILD TYPE;

ANOIKIS; CELL ADHESION; CELL SURVIVAL; HUMANS; MELANOCYTES; MELANOMA; POINT MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 77954761299     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.117     Document Type: Letter

References (14)

1. Boisvert-Adamo K, Aplin AE (2006) B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis. Oncogene 25:4848-4856
2. Boisvert-Adamo K, Longmate W, Abel EV et al. (2009) Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res 7:549-556
3. Collins NL, Reginato MJ, Paulus JK et al. (2005) G1/S cell cycle arrest provides anoikis resistance through Erk-mediated Bim suppression. Mol Cell Biol 25:5282-5291
4. Gilmore AP (2005) Anoikis. Cell Death Differ 12(Suppl 2):1473-1477
5. Goldstein NB, Johannes WU, Gadeliya AV et al. (2009) Active N-Ras and B-Raf inhibit anoikis by downregulating Bim expression in mela-nocytic cells. J Invest Dermatol 129:432-437
6. Gray-Schopfer VC, Cheong SC, Chong H et al. (2006) Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer 95:496-505
7. Haferkamp S, Scurr LL, Becker TM et al. (2009) Oncogene-induced senescence does not require the p16(INK4a) or p14ARF melanoma tumor suppressors. J Invest Dermatol 128:1983-1991
8. Michaloglou C, Vredeveld LC, Soengas MS et al. (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720-724
9. Pavey S, Johansson P, Packer L et al. (2004) Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncgene 23:4060-4067
10. Platz A, Egyhazi S, Ringborg U et al. (2008) Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 1:395-405
11. Reifenberger J, Knobbe CB, Wolter M et al. (2002) Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int J Cancer 100:549-556
12. Sensi M, Nicolini G, Petti C et al. (2006) Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 25:3357-3364
13. Thomas NE (2006) BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res 16:97-103
14. Viros A, Fridlyand J, Bauer J et al. (2008) Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 5:e120